Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327862 | 0.86 | BRD4 (0.68) | TSHRMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL22734270 | 0.86 | TSHR (0.58) | TSHRMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL28000025 | 0.85 | HSD17B13 (0.55) | TSHRMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL10340271 | 0.81 | KDM4E (0.77) | TSHRMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL1168830 | 0.78 | HSD17B13 (0.53) | TSHRMAPTALDH1A1GAAGFER | |
| SCHEMBL8639229 | 0.78 | MAPT (0.71) | TSHRMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8049389 | 0.76 | MEN1 (0.76) | TSHRMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL31393812 | 0.76 | MEN1 (0.76) | TSHRMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL9295845 | 0.76 | BRD4 (0.58) | TSHRMAPTKDM4EALDH1A1GAA | |
| SCHEMBL10340210 | 0.76 | MAPT (0.71) | TSHRMAPTKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279487-B2 | Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1467970-B1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1467970-A4 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050119482-A1 | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | disclosed |
| EP-1467970-A1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062204-A1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119482-A1 | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors | HCLS1, POLR2A, CCNT1 | TSHR 1479/4885MAPT 3716/4885KDM4E 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.